1. Home
  2. AURA vs ATYR Comparison

AURA vs ATYR Comparison

Compare AURA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AURA
  • ATYR
  • Stock Information
  • Founded
  • AURA 2007
  • ATYR 2005
  • Country
  • AURA United States
  • ATYR United States
  • Employees
  • AURA N/A
  • ATYR N/A
  • Industry
  • AURA Biotechnology: Pharmaceutical Preparations
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AURA Health Care
  • ATYR Health Care
  • Exchange
  • AURA Nasdaq
  • ATYR Nasdaq
  • Market Cap
  • AURA 370.1M
  • ATYR 327.0M
  • IPO Year
  • AURA 2021
  • ATYR 2015
  • Fundamental
  • Price
  • AURA $6.34
  • ATYR $3.13
  • Analyst Decision
  • AURA Strong Buy
  • ATYR Strong Buy
  • Analyst Count
  • AURA 4
  • ATYR 6
  • Target Price
  • AURA $22.75
  • ATYR $18.60
  • AVG Volume (30 Days)
  • AURA 383.6K
  • ATYR 1.7M
  • Earning Date
  • AURA 03-24-2025
  • ATYR 03-13-2025
  • Dividend Yield
  • AURA N/A
  • ATYR N/A
  • EPS Growth
  • AURA N/A
  • ATYR N/A
  • EPS
  • AURA N/A
  • ATYR N/A
  • Revenue
  • AURA N/A
  • ATYR $235,000.00
  • Revenue This Year
  • AURA N/A
  • ATYR $1,387.23
  • Revenue Next Year
  • AURA N/A
  • ATYR $873.22
  • P/E Ratio
  • AURA N/A
  • ATYR N/A
  • Revenue Growth
  • AURA N/A
  • ATYR N/A
  • 52 Week Low
  • AURA $5.77
  • ATYR $1.42
  • 52 Week High
  • AURA $12.38
  • ATYR $4.66
  • Technical
  • Relative Strength Index (RSI)
  • AURA 34.98
  • ATYR 38.96
  • Support Level
  • AURA $5.77
  • ATYR $3.20
  • Resistance Level
  • AURA $7.73
  • ATYR $3.94
  • Average True Range (ATR)
  • AURA 0.46
  • ATYR 0.32
  • MACD
  • AURA -0.13
  • ATYR -0.06
  • Stochastic Oscillator
  • AURA 29.08
  • ATYR 11.19

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: